214 related articles for article (PubMed ID: 30362288)
1. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.
Peyvandi F; Mamaev A; Wang JD; Stasyshyn O; Timofeeva M; Curry N; Cid AR; Yee TT; Kavakli K; Castaman G; Sytkowski A
J Thromb Haemost; 2019 Jan; 17(1):52-62. PubMed ID: 30362288
[TBL] [Abstract][Full Text] [Related]
2. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.
Gill JC; Castaman G; Windyga J; Kouides P; Ragni M; Leebeek FW; Obermann-Slupetzky O; Chapman M; Fritsch S; Pavlova BG; Presch I; Ewenstein B
Blood; 2015 Oct; 126(17):2038-46. PubMed ID: 26239086
[TBL] [Abstract][Full Text] [Related]
3. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
Mannucci PM; Kempton C; Millar C; Romond E; Shapiro A; Birschmann I; Ragni MV; Gill JC; Yee TT; Klamroth R; Wong WY; Chapman M; Engl W; Turecek PL; Suiter TM; Ewenstein BM;
Blood; 2013 Aug; 122(5):648-57. PubMed ID: 23777763
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
Windyga J; von Depka-Prondzinski M;
Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3.
Bauer A; Friberg-Hietala S; Smania G; Wolfsegger M
J Blood Med; 2023; 14():399-411. PubMed ID: 37332615
[TBL] [Abstract][Full Text] [Related]
7. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
Lethagen S; Kyrle PA; Castaman G; Haertel S; Mannucci PM;
J Thromb Haemost; 2007 Jul; 5(7):1420-30. PubMed ID: 17439628
[TBL] [Abstract][Full Text] [Related]
8. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
Haemophilia; 1998; 4 Suppl 3():53-62. PubMed ID: 10028320
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in Patients With von Willebrand Disease Receiving Recombinant von Willebrand Factor on Demand and in Surgical Settings: Chart Review.
Sun SX; Lowndes S; Willock R; Jones C; Brighton S
Clin Appl Thromb Hemost; 2023; 29():10760296231177294. PubMed ID: 37282513
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures.
Desprez D; Drillaud N; Flaujac C; Volot F; Pan-Petesch B; Beurrier P; Cussac V; Feugeas O; Pailler Y; Callegarin A; Trossaërt M; de Raucourt E
Haemophilia; 2021 Mar; 27(2):270-276. PubMed ID: 33550648
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P).
Thompson AR; Gill JC; Ewenstein BM; Mueller-Velten G; Schwartz BA;
Haemophilia; 2004 Jan; 10(1):42-51. PubMed ID: 14962219
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
Borel-Derlon A; Federici AB; Roussel-Robert V; Goudemand J; Lee CA; Scharrer I; Rothschild C; Berntorp E; Henriet C; Tellier Z; Bridey F; Mannucci PM
J Thromb Haemost; 2007 Jun; 5(6):1115-24. PubMed ID: 17403090
[TBL] [Abstract][Full Text] [Related]
15. Hemostatic potential of recombinant von Willebrand factor and standard or pegylated extended half-life recombinant factor VIII on thrombus formation under high shear flow.
Yaoi H; Shida Y; Ogiwara K; Nogami K
Thromb J; 2023 Dec; 21(1):122. PubMed ID: 38066509
[TBL] [Abstract][Full Text] [Related]
16. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
Leebeek FWG; Peyvandi F; Escobar M; Tiede A; Castaman G; Wang M; Wynn T; Baptista J; Wang Y; Zhang J; Mellgård B; Özen G
Blood; 2022 Jul; 140(2):89-98. PubMed ID: 35439298
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.
Gill JC; Ewenstein BM; Thompson AR; Mueller-Velten G; Schwartz BA;
Haemophilia; 2003 Nov; 9(6):688-95. PubMed ID: 14750934
[TBL] [Abstract][Full Text] [Related]
20. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]